Trial Profile
A Phase I study of TSU-68 in combination with Carboplatin and Paclitaxel in patients with Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2016
Price :
$35
*
At a glance
- Drugs Orantinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 01 Jun 2016 New trial record